Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Denali Therapeutics (DNLI) Income from Continuing Operations (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Income from Continuing Operations for 9 consecutive years, with 128447000.0 as the latest value for Q4 2025.

  • Quarterly Income from Continuing Operations fell 12.0% to 128447000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 512438000.0 through Dec 2025, down 21.23% year-over-year, with the annual reading at 512540000.0 for FY2025, 21.23% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 128447000.0 at Denali Therapeutics, down from 126902000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 183383000.0 in Q2 2023, with the low at 132970000.0 in Q1 2025.
  • Average Income from Continuing Operations over 5 years is 84910850.0, with a median of 100577500.0 recorded in 2023.
  • The sharpest move saw Income from Continuing Operations surged 411.91% in 2023, then crashed 154.0% in 2024.
  • Over 5 years, Income from Continuing Operations stood at 75261000.0 in 2021, then crashed by 31.11% to 98678000.0 in 2022, then decreased by 21.07% to 119473000.0 in 2023, then increased by 4.01% to 114685000.0 in 2024, then decreased by 12.0% to 128447000.0 in 2025.
  • According to Business Quant data, Income from Continuing Operations over the past three periods came in at 128447000.0, 126902000.0, and 124119000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.